Menu
The firm is one of the most important Indian manufacturers and suppliers of active pharmaceutical ingredients (APIs), with a strong emphasis on research and development. It has a specialised product portfolio of 38 APIs focused on distinct therapeutic categories such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic, and antiallergic as of October 31, 2021.
Throughout Fiscal 2017 and 2021, the firm has continuously been the top exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, accounting for 45-50 percent and 60-65 percent, respectively, of India’s API exports. It was one of the top exporters of Salbutamol Sulphate in India, accounting for 31% of India’s API exports in volume terms in FY 2021.
Its pharmaceutical business is divided into two divisions: domestic sales and export sales. Its goods were exported to 86 countries to 1,296 clients, including 346 wholesalers, between 1 April 2020 and 31 October 2021.
| Subscription Dates | 16 – 20 December 2021 |
| Price Band | INR265 – 274 per share |
| Fresh issue | INR200 crore |
| Offer For Sale | INR500 crore |
| Total IPO size | INR700 crore |
| Minimum bid (lot size) | 54 shares |
| Face Value | INR 2 per share |
| Retail Allocation | 10% |
| Listing On | NSE, BSE |
FY2019 | FY2020 | |
Revenue | 285.9 | 322.7 |
Expenses | 213.1 | 213.3 |
Net income | 39.4 | 73.4 |
Margin (%) | 13.8 | 22.7 |
FY2021 | Q1 FY2022 | |
Revenue | 396.2 | 230.1 |
Expenses | 218.1 | 131.4 |
Net income | 123.8 | 66.0 |
Margin (%) | 31.2 | 28.7 |
FY2019 | FY2020 | |
EPS | 5.39 | 10.03 |
PE ratio | – | – |
RONW (%) | 42.03 | 49.20 |
ROCE (%) | ||
EBITDA (%) | 25.45 | 33.92 |
Debt/Equity | 0.94 | 0.55 |
NAV | – | – |
FY2021 | |
EPS | 16.92 |
PE ratio | 15.66 – 16.19 |
RONW (%) | 46.04 |
ROCE (%) | |
EBITDA (%) | 44.96 |
Debt/Equity | 0.26 |
NAV | 36.75 |
Date | GMP | Kostak | Subject to Sauda |
27 Dec 2021 | INR150 | INR200 | INR4,000 |
25 Dec 2021 | INR130 | INR200 | INR4,000 |
24 Dec 2021 | INR150 | INR200 | INR4,000 |
23 Dec 2021 | INR120 | INR200 | INR3,500 |
22 Dec 2021 | INR100 | INR150 | INR3,000 |
Listed On : Dec 28, 2021
Issue Price : Coming Soon
Listing Day Close : Coming Soon
Listing Day Gain/Loss (%) : Coming Soon
NSE : NA
ISIN CODE : INE07RO01027
BSE : 543434
Angel One – Subscribe
Anand Rathi – Subscribe for long term
Ashika Research – Subscribe
BP Wealth – Subscribe
Canara Bank Securities – Subscribe
Choice Broking – Subscribe
Elite Wealth – Subscribe
Hem Securities – Subscribe
ICICIdirect – Unrated
Marwadi Financial Services – Subscribe
Motilal Oswal – Subscribe
Nirmal Bang – Subscribe
Samco Securities – Subscribe
SMC Global – 2.5/5
Ventura Securities – Subscribe
| IPO Opening Date | 16 December 2021 |
| IPO Closing Date | 20 December 2021 |
| Finalisation of Basis of Allotment | 23 December 2021 |
| Initiation of refunds | 24 December 2021 |
| Transfer of shares to demat accounts | 27 December 2021 |
| Listing Date | 28 December 2021 |
Supriya Lifescience Limited
207/208, Udyog Bhavan,
Sonawala Road, Goregaon – East,
Mumbai – 400063, Maharashtra
Phone: +91 22-40332727
Email: cs@supriyalifescience.com
Website: www.supriyalifescience.com
Link Intime India Private Limited
C-101, 1st Floor,
247 Park Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai – 400 083
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email: supriyalife.ipo@linkintine.co.in
Website: http://www.linkintime.co.in
Category | Shares Offered | Day 1 |
QIB | 79,24,527 | 0.00 |
NII | 39,62,263 | 0.66 |
Retail | 26,41,509 | 11.84 |
Total | 1,45,28,299 | 2.33 |
Category | Day 2 | Day 3 |
QIB | 0.53 | 31.83 |
NII | 2.90 | 161.22 |
Retail | 25.38 | 55.75 |
Total | 5.69 | 71.47 |
Supriya Lifescience Limited IPO is a main-board IPO of ₹265 to ₹274 per equity share of the face value of ₹2 aggregating up to [.] Eq Shares of ₹2
(aggregating up to ₹700.00 Cr). The fresh issue is priced at [.] Eq Shares of ₹2
(aggregating up to ₹200.00 Cr). The minimum order quantity is 54 Shares. The initial public offering (IPO) date Dec 16, 2021. The registrar for the IPO is Link Intime India Private Ltd. The shares are proposed for listing on the NSE and BSE.
The Supriya Lifescience Limited IPO opening date is Dec 16, 2021. and the closing date is Dec 20, 2021.
Supriya Lifescience Limited IPO Market lot size is 54 Shares and the minimum order quantity is 54 Shares.
The Basis of Allotment for Supriya Lifescience Limited IPO will be done on Dec 23, 2021 and the allotted shares will be credited to your demat account by Dec 27, 2021. Check the Supriya Lifescience Limited IPO allotment status.
The Supriya Lifescience Limited IPO listing date is Dec 28, 2021.
Supriya Lifescience Limited IPO can be submitted online using either UPI or ASBA as a payment method. The ASBA IPO application is available in your bank’s net banking. Brokers who do not provide banking services provide UPI IPO applications. Learn more about online IPO applications from Zerodha, Upstox, 5Paisa, Edelweiss, ICICI Bank, HDFC Bank, and SBI Bank.
© 2021 All rights reserved